REDWOOD CITY, Calif., Nov. 03, 2015 (GLOBE NEWSWIRE) -- Relypsa, Inc. (Nasdaq:RLYP) today announced that the company will present at two upcoming investor conferences in November 2015.
John A. Orwin, president and chief executive officer, will present and provide corporate updates at the following events:
- Credit Suisse 24th Annual Healthcare Conference in Scottsdale, Ariz.: November 10, 2015, at 2:30 p.m. MT
- Stifel 2015 Healthcare Conference in New York City, N.Y.: November 18, 2015, at 3:45 p.m. ET
To access the live webcasts and subsequent archived recordings of these presentations, please visit Relypsa's website at http://investor.relypsa.com/events.cfm.
About Relypsa, Inc.
Relypsa, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of polymeric medicines for patients with conditions that are often overlooked and undertreated and can be addressed in the gastrointestinal tract. The Company’s first medicine, VeltassaTM (patiromer) for oral suspension, was developed based on Relypsa’s rich legacy in polymer science. Veltassa is approved in the United States for the treatment of hyperkalemia. Veltassa has intellectual property protection until 2030 in the United States and 2029 in the European Union. More information is available at www.relypsa.com.
Associate Director, Investor Relations